Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

METABOLISM

Can metabolomic profiling predict response to therapy?

Nature Reviews Rheumatology volume 15, pages 129–130 (2019)Cite this article

Subjects

Shifts in cellular metabolism are central to activation, differentiation and proliferation of inflammatory cells and can contribute to the pathogenesis of inflammatory diseases. Integrating metabolomics data with other omics data is a major challenge but might enable clinicians to stratify stages of disease and response to therapy in patients with rheumatoid arthritis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ajeganova, S. & Huizinga, T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther. Adv. Musculoskelet. Dis. 9, 249–262 (2017).

    Article  CAS  Google Scholar 

  2. Teitsma, X. M. et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res. Ther. 20, 230 (2018).

    Article  Google Scholar 

  3. DeBerardinis, R. J. & Thompson, C. B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148, 1132–1144 (2012).

    Article  CAS  Google Scholar 

  4. Bijlsma, J. W. J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388, 343–355 (2016).

    Article  CAS  Google Scholar 

  5. Kanarek, N. et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature 559, 632–636 (2018).

    Article  CAS  Google Scholar 

  6. Teitsma, X. M. et al. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. Arthritis Res. Ther. 19, 10 (2017).

    Article  Google Scholar 

  7. Teitsma, X. M. et al. Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213767 (2018).

    Article  PubMed  Google Scholar 

  8. Wang, J. et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 3, e003199 (2013).

    Article  Google Scholar 

  9. Kapoor, S. R. et al. Metabolic profiling predicts response to anti-TNFα therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 65, 1448–1456 (2013).

    Article  CAS  Google Scholar 

  10. Young, S. P. et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheumatol. 65, 2015–2023 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

C. M. M. is funded by a Research Fellowship from the National Institute for Health Research.

Author information

Authors and Affiliations

  1. Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

    Catherine M. McGrath & Stephen P. Young

Authors
  1. Catherine M. McGrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen P. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen P. Young.

Ethics declarations

Competing interests

C. M. M. declares that she has received honoraria from Pfizer. S.P.Y. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McGrath, C.M., Young, S.P. Can metabolomic profiling predict response to therapy?. Nat Rev Rheumatol 15, 129–130 (2019). https://doi.org/10.1038/s41584-018-0136-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-018-0136-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research